Global Cord Blood Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Global Cord Blood's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Recent updates
Global Cord Blood GAAP EPS of $0.14, revenue of $46.88M
Jul 05Pounce On Global Cord For The Year Of The Tiger
Apr 29Global Cord Blood Corp. Looks Anemic On Slow Growth, Regulatory Concerns
Apr 08Global Cord Blood: With 6.0x P/E And 24% EPS CAGR, Subscriber Growth Continues
Dec 01Global Cord Blood Is An Undervalued Business With Accelerating Growth, Benefiting From China's Policy Changes
Jul 30Global Cord Blood: New China Policy Catalyst, 146% Net Cash And 24% EPS CAGR
Jul 01Global Cord Blood announces NHC policy update
Jan 05Global Cord Blood reports FQ2 results
Nov 24Revenue & Expenses BreakdownBeta
How Global Cord Blood makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 22 | 1,243 | 501 | 429 | 22 |
31 Dec 21 | 1,248 | 524 | 423 | 23 |
30 Sep 21 | 1,222 | 506 | 423 | 25 |
30 Jun 21 | 1,194 | 512 | 418 | 25 |
31 Mar 21 | 1,160 | 508 | 412 | 24 |
31 Dec 20 | 1,157 | 478 | 413 | 22 |
30 Sep 20 | 1,201 | 506 | 424 | 19 |
30 Jun 20 | 1,229 | 495 | 441 | 21 |
31 Mar 20 | 1,221 | 471 | 452 | 21 |
31 Dec 19 | 1,173 | 465 | 459 | 22 |
30 Sep 19 | 1,093 | 381 | 445 | 19 |
30 Jun 19 | 1,026 | 326 | 422 | 17 |
31 Mar 19 | 987 | 291 | 404 | 15 |
31 Dec 18 | 968 | 231 | 437 | 13 |
30 Sep 18 | 959 | 239 | 444 | 13 |
30 Jun 18 | 946 | 242 | 461 | 13 |
31 Mar 18 | 937 | 237 | 463 | 13 |
31 Dec 17 | 906 | 235 | 421 | 12 |
30 Sep 17 | 862 | 221 | 402 | 12 |
30 Jun 17 | 811 | 170 | 381 | 11 |
31 Mar 17 | 760 | 116 | 368 | 10 |
31 Dec 16 | 715 | 96 | 347 | 9 |
30 Sep 16 | 683 | 91 | 329 | 9 |
30 Jun 16 | 671 | 93 | 321 | 9 |
31 Mar 16 | 663 | 91 | 318 | 9 |
31 Dec 15 | 669 | 87 | 314 | 9 |
30 Sep 15 | 667 | 79 | 295 | 9 |
30 Jun 15 | 647 | 83 | 277 | 9 |
31 Mar 15 | 635 | 99 | 260 | 10 |
31 Dec 14 | 624 | 107 | 241 | 10 |
30 Sep 14 | 608 | 116 | 236 | 10 |
30 Jun 14 | 597 | 115 | 230 | 10 |
31 Mar 14 | 573 | 117 | 225 | 10 |
31 Dec 13 | 554 | 109 | 220 | 9 |
30 Sep 13 | 553 | 106 | 216 | 9 |
30 Jun 13 | 540 | 106 | 213 | 9 |
Quality Earnings: Insufficient data to determine if CORB.F has high quality earnings.
Growing Profit Margin: Insufficient data to determine if CORB.F's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CORB.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare CORB.F's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if CORB.F's earnings growth over the past year exceeded the Healthcare industry average.
Return on Equity
High ROE: CORB.F has a negative Return on Equity (0%), as it is currently unprofitable.